Table 1 Characteristics and differences by serum CA 19-9 levels in patients with advanced-stage lung adenocarcinoma
From: The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma
Patient characteristics | Total n (%) (n = 246) | CA 19-9 positive n (%) (n = 76) | CA 19-9 negative n (%) (n = 170) | P |
|---|---|---|---|---|
Age (years) | ||||
 SD | 10.4 | 10.7 | 10.2 | 0.160 |
 Mean | 67.1 | 68.5 | 66.5 | |
Sex | ||||
 Male | 154 (63) | 47 (62) | 107 (63) | 0.887 |
 Female | 92 (37) | 29 (38) | 63 (37) | |
Smoking status | ||||
 Never | 101 (41) | 29 (38) | 72 (42) | 0.577 |
 Current or former | 145 (59) | 47 (62) | 98 (58) | |
ECOG PS | ||||
 0 or 1 | 184 (75) | 46 (61) | 138 (81) | <0.001 |
 2–4 | 62 (25) | 30 (39) | 32 (19) | |
Stage | ||||
 IIIB | 26 (11) | 6 (8) | 20 (12) | 0.501 |
 IV | 220 (89) | 70 (92) | 150 (88) | |
EGFR status | ||||
 Mutated | 100 (41) | 30 (39) | 70 (41) | 0.888* |
  Exon 19 deletion | 45 (18) | 16 (21) | 29 (17) | |
  Exon 21 point mutation | 48 (20) | 11 (14) | 37 (22) | |
  Others | 7 (3) | 3 (4) | 4 (2) | |
 WT or uninvestigated | 146 (59) | 46 (61) | 100 (59) | |
Inflammatory lung disease | ||||
 Present | 22 (9) | 10 (13) | 12 (7) | 0.147 |
 Absent | 224 (91) | 66 (87) | 158 (93) | |
Serum CEA | ||||
 Positive | 163 (66) | 53 (70) | 110 (65) | 0.469 |
 Negative | 83 (34) | 23 (30) | 60 (35) | |
Serum CYFRA 21-1 | ||||
 Positive | 155 (63) | 59 (78) | 96 (56) | 0.002 |
 Negative | 91 (37) | 17 (22) | 74 (44) | |
Chemotherapy | ||||
 Platinum doublet | 170 (69) | 43 (57) | 127 (75) | 0.007 |
 Others | 76 (31) | 33 (43) | 43 (25) | |